Bacterial pathogens are becoming increasingly resistant to antibiotics. As an alternative therapeutic strategy, phage therapy reagents containing purified viral lysins have been developed against Grampositive organisms but not against Gram-negative organisms due to the inability of these types of drugs to cross the bacterial outer membrane. We solved the crystal structures of a Yersinia pestis outer membrane transporter called FyuA and a bacterial toxin called pesticin that targets this transporter. FyuA is a β-barrel membrane protein belonging to the family of TonB dependent transporters, whereas pesticin is a soluble protein with two domains, one that binds to FyuA and another that is structurally similar to phage T4 lysozyme. The structure of pesticin allowed us to design a phage therapy reagent comprised of the FyuA binding domain of pesticin fused to the N-terminus of T4 lysozyme. This hybrid toxin kills specific Yersinia and pathogenic E. coli strains and, importantly, can evade the pesticin immunity protein (Pim) giving it a distinct advantage over pesticin. Furthermore, because FyuA is required for virulence and is more common in pathogenic bacteria, the hybrid toxin also has the advantage of targeting primarily disease-causing bacteria rather than indiscriminately eliminating natural gut flora.
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colicin | muramidase | TonB-dependent transport | plague B acteriophages are viruses that have a prolific ability to infect, multiply within, and subsequently eliminate large numbers of bacteria. Their potential for use in microbial therapy was recognized shortly after their discovery in the late 1910s (1, 2) . Phage therapy was initially developed, but later fell out of favor, when small molecule antibiotics became cheaper and easier to manufacture in large homogeneous quantities. More recently, the emergence of antibiotic resistant bacterial strains has renewed interest in using phages or their components in therapy, agriculture, food, and water treatment (3) . Reagents have been developed using phage derived proteins called lysins to clear in vivo infections of Gram-positive bacteria such as Streptococcus pneumoniae (4) and Bacillus anthracis (5) . Clearance occurs because lysins hydrolyze the surface exposed peptidoglycan that forms the cell wall of Gram-positive bacteria causing cell rupture ; however, a major limitation of this approach is that it cannot be applied to Gram-negative bacteria because viral lysins cannot cross the outer membrane without help from accessory proteins or membrane-disrupting agents. The outer membrane effectively shields peptidoglycan from degradation by the externally added lysin.
We solved the crystal structure of a protein toxin from Y. pestis that showed us how to engineer a phage lysin capable of killing Gram-negative bacteria. This protein, called pesticin, belongs to a class of bacterial proteins known as bacteriocins (referred to as colicins when they target E. coli). Bacteriocins are produced by bacteria to kill related bacterial strains in times of stress. Bacteria producing the bacteriocin protect themselves by expressing an immunity protein to inhibit activity of the toxin (6) . Y. pestis produces pesticin to promote virulence. Pesticin, pesticin immunity protein, and plasminogen activator (Pla) are encoded on a ∼10 kb plasmid called pPCP1 (7) . Pla facilitates invasion in bubonic plague and, as such, is an important virulence factor (8, 9) . When strains lose the pPCP1 plasmid, they are killed by pesticin thus ensuring maximal virulence in the bacterial population.
Bacteriocins belong to two classes. Type A bacteriocins depend on the Tol system to traverse the outer membrane, whereas type B bacteriocins require the Ton system. For both classes, the primary interaction that triggers the translocation process occurs between the bacteriocin and a specific outer membrane receptor protein.
Pesticin has been classified as a type B bacteriocin because killing depends on the products of the tonB, exbB, and exbD genes and, like other type B bacteriocins, pesticin has a TonB box motif located near its N-terminus (10) . In addition to tonB, exbB, and exbD, these bacteria must express a receptor gene-fyuA-in order to be killed by pesticin. FyuA is an integral outer membrane protein that acts as the receptor for pesticin (11) . It is also a major virulence factor for some Yersinia strains (12, 13) and certain pathogenic E. coli (14, 15) . Although Y. pestis also expresses FyuA in its outer membrane, it is protected from pesticin-induced cell death by the product of the pesticin immunity gene that is always found adjacent to the pesticin gene (10) . Interaction between FyuA and pesticin is necessary to trigger the import of pesticin across the outer membrane into the periplasm. Once inside the periplasm, pesticin kills the cell by degrading peptidoglycan (16) through a muramidase (lysozyme) activity (17) .
Here, we report the first production of an engineered lysin that can directly kill Gram-negative bacteria. We solved the 2.1 Å structure of pesticin and used the structure to guide engineering of a "hybrid lysin." Pesticin consists of two domains: one that targets and binds to FyuA, and the other that degrades peptidoglycan. The engineered hybrid consists of T4 lysozyme, which is an archetypal lysin, attached to the FyuA-targeting domain derived from pesticin. To visualize the import machinery better, we solved the structure of FyuA at 3.2 Å and the hybrid toxin at 2.6 Å resolution. FyuA is a TonB-dependent iron transporter (18) consisting of a 22-strand β-barrel with a plug domain inserted in the pore. The hybrid toxin resembles pesticin and retains the same two-domain architecture. We show that the hybrid lysin crosses the outer membrane and kills cells not only in a model E. coli system but also in bacterial pathogens. Importantly, killing only affects cells that produce FyuA (11) . The action of the hybrid lysin is unaffected by Pim (10), which is a protein that some Yersiniae produce to inhibit peptidoglycan degrading enzymes.
The hybrid lysin can, therefore, potentially be used against any strain expressing FyuA.
Results
Structure Determination of Y. pestis FyuA and Pesticin. We began this project by determining the structure of FyuA, a 71 kDa outer membrane transporter that normally transports ferric yersiniabactin (Fe-Ybt) and is important for virulence in certain Yersinia and E. coli strains. FyuA was expressed in E. coli, purified and crystallized using the detergents LDAO and C 8 E 4 . Crystals diffracted to 3.2 Å resolution, and the structure was solved by single wavelength anomalous dispersion (Table S1 ). The structure of FyuA has features typical of the TonB-dependent transporter family (Fig. 1A) (18) including a membrane-spanning 22-strand β-barrel whose pore is blocked by a plug domain. On the periplasmic side of the membrane, the individual β-strands of the barrel are connected by short turns, whereas on the extracellular side strands are connected by long extracellular loops L1-L11. A portion of L8 is disordered (residues 487-492). The TonB box motif (STLVVTA, residues [8] [9] [10] [11] [12] [13] [14] is essential for interactions with TonB-ExbB-ExbD (13, 19) and is only partially visible in the structure (residues 1-12 are disordered). Mutations in the TonB box prevent transport of siderophores and bacteriocins (6) .
To learn more about how pesticin kills bacteria expressing FyuA, we solved the 2.1 Å crystal structure of pesticin (40 KDa) using multiwavelength anomalous dispersion (Table S1 ). The structure of pesticin consists of two domains joined by a short linker (Fig. 1B) . The N-terminal domain is formed by a sevenstrand antiparallel β-sheet with two α-helices inserted between strands 5 and 6 and an additional α-helix following strand 7. The C-terminal domain of pesticin is primarily α-helical, except for a small irregular antiparallel three-strand β-sheet (Fig. 1B) . The N-terminal 13 residues are disordered in the structure. This region includes the TonB box motif (DTMVV, residues 3-7) (10) which is necessary for type B bacteriocins to be translocated across the outer membrane. Other regions that could not be resolved include residues 25-34 (25-32 in noncrystallographic symmetry related copy B) and the C-terminal residue.
Pesticin Shares Structural Similarity with Phage T4 Lysozyme. Pesticin does not resemble any other known bacteriocin in sequence or structure (6); so, we analyzed the pesticin fold using the DALI server (20) to search for other structural homologs. DALI analysis revealed a striking similarity between the C-terminal domain of pesticin and phage T4 lysozyme (21) that had not been postulated prior to the structure determination because the sequence similarity is low (Fig. 1C and Fig. S1 ). T4 lysozyme is an archetypal lysin, and members of the T4 lysozyme family have an essential catalytic triad corresponding to E11, D20, and T26 ( Fig. 1 B-D) (22) . Two of these residues are conserved in pesticin: E178 and T201. We confirmed that E178 and T201 are active site residues by mutating them to alanine, which completely abolished pesticin activity using a bactericidal assay (Fig. S2 ).
Structure Determination of a Pesticin-T4 Lysozyme Hybrid. The structural and functional resemblance between the two proteins suggested that we could create a hybrid lysin by fusing the N-terminal domain of pesticin to T4 lysozyme, an idea that only became clear The TonB box of FyuA was mostly disordered and not observed in the crystal structure. In the periplasmic view of FyuA, the location of the TonB box is not shown for clarity. (B) The crystal structure of pesticin consists of two distinct domains: The predominantly β-sheet N-terminal domain (FyuA binding domain) in purple and encompasses residues 1-164. The mainly α-helical C-terminal domain (residues 168-357) in gold (killing domain). A short linker connects the two domains and is shown in cyan that spans residues 165-167. The TonB box of pesticin was disordered and not observed in the crystal structure. The residues mutated in this study are labelled and shown in stick representation and include residues in the presumed active site of pesticin. (C) To illustrate that the C-terminal domain of pesticin is structurally similar to T4 lysozyme, the crystal structure of T4 lysozyme (green) (PDB code ¼ 2LZM) is represented in the same orientation as the C-terminal domain of pesticin. Similarity between the two proteins is primarily structural; there is little sequence identity except for a partial conservation of active site residues that is apparent after a structural alignment. (D) Superimposition of the pesticin (gold) and T4 lysozyme (green) active sites shows that the catalytic threonine and glutamate residues are conserved in pesticin, whereas the catalytic aspartate in lysozyme is replaced by a proline in pesticin. Therefore, pesticin shares a functional resemblance to T4 lysozyme, but the active sites are not identical. For clarity, representation of secondary structure elements was omitted in D.
upon analyzing the pesticin structure. The hybrid lysin thus consists of a Y. pestis "FyuA-targeting" domain and a T4 phage "killing" domain (Fig. S3) . We crystallized the hybrid lysin and solved the structure by molecular replacement to 2.6 Å (Table S1 and Fig. S4A ). Like pesticin, the hybrid lysin consists of two domains folded similarly to wild type pesticin (Fig. S4 D and E) . The individual domains have an rmsd of 0.5 Å with their counterparts in pesticin. Two slightly different conformations were observed within the asymmetric unit of the hybrid structure with the only difference being a small rotation of the T4 lysozyme domain relative to the targeting domain; however, the position and orientation of the lysozyme killing domain of the hybrid was rotated ∼90 degrees relative to the killing domain of wild type pesticin.
Pesticin and the Hybrid Lysin Specifically Target Cells Expressing FyuA.
To evaluate the engineered hybrid lysin, we needed a method to assess wild type pesticin activity. We established a bactericidal assay using E. coli cells expressing Y. pestis FyuA from a pET20b vector. As expected, we found that pesticin was able to kill E. coli cells expressing FyuA ( Fig. 2A) , whereas control cells containing unmodified pET20b were completely resistant (Fig. 2C) . We then used this assay to determine whether our pesticin-lysozyme hybrid would kill E. coli cells expressing FyuA. The hybrid lysin was able to kill fyuA + cells in the bactericidal assay (though to a lesser extent than pesticin). For the fyuA -cells (Null), the sample treated with pesticin survived similarly to the untreated control, whereas the sample treated with hybrid lysin showed low levels of cell death. The level of killing, however, was small compared to the level seen when the hybrid lysin was added to cells expressing FyuA. These data indicate that killing by the hybrid largely depends on FyuA expression ( Fig. 2 A and C) . We also confirmed that fyuA + cells are not killed by the addition of purified T4 lysozyme (Fig. S2) . Because cell death arises from peptidoglycan degradation in the periplasm, our results indicate that T4 lysozyme was transported across the outer membrane when attached to the N-terminal domain of pesticin.
We tested pesticin's ability (at high and low concentrations) to inhibit the growth of fyuA + cells and found that each concentration inhibited growth similarly (Fig. S5) . In contrast, colicin Ia is self-inhibitory at high concentrations because colicin Ia requires two copies of its receptor Cir, one for initial cell binding and the other for translocation across the outer membrane (23) . As a result, at high concentration colicin Ia binds all the available Cir on the cell surface and then cannot find free Cir for translocation. Because high concentrations of pesticin inhibited growth similarly compared to low concentrations, this suggests that pesticin only requires one copy of FyuA to bind and enter the cell or that another unknown receptor could be involved.
The Hybrid Lysin Is Not Inactived by Pesticin Immunity Protein. We next asked whether Pim could inhibit the toxicity of our hybrid lysin. Y. pestis strains producing pesticin are protected from cell death by Pim. To test whether the hybrid lysin could overcome the natural immunity conferred by Pim, we constructed a vector that expresses the fyuA and pim genes concomitantly. Fig. 2B shows that the expression of Pim protects against killing by pesticin: E. coli cells transformed with this vector were not killed by pesticin at a concentration of 100 μg∕mL. In contrast, adding 100 μg∕mL of the hybrid lysin to cells expressing Pim and FyuA resulted in cell death (Fig. 2B) . Therefore, the pesticin-lysozyme hybrid can overcome the natural immunity of Pim-producing strains giving it an advantage over pesticin by extending its potential therapeutic application to a wide variety of Yersiniae.
Yersinia and UPEC Strains Are Sensitive To Pesticin and the Hybrid
Lysin. To confirm that our observations in the E. coli model system were consistent with the response of bacteria that naturally express FyuA, we tested Y. pestis and Y. pseudotuberculosis for their sensitivity to pesticin and the hybrid lysin (Fig. S6) . Pesticin killed Y. pseudotuberculosis and Y. pestis KIM10+ but not Y. pestis KIM6+. The presence of the pPCP1 plasmid (24) that encodes pesticin and Pim renders KIM6+ insensitive to pesticin action. On the other hand, Y. pestis KIM6+ was sensitive to killing by the hybrid lysin, though to a lesser degree compared to Y. pestis KIM10+. These data indicate that the hybrid can circumvent the action of Pim in Y. pestis. A possible explanation for why the hybrid lysin does not kill Y. pestis KIM6+ as efficiently as Y. pestis KIM10+ could be the presence of the outer membrane protease Pla in the KIM6+ strain but not in the KIM10+ strain. It is possible that Pla can degrade the hybrid lysin on the cell surface before it can be transported to the periplasm. Because the hybrid lysin kills E. coli in the presence or absence of Pim at similar levels ( Fig. 2) , we think it is unlikely that Pim partially deactivates the hybrid lysin in Y. pestis but not in E. coli.
The bactericidal activities of pesticin and hybrid lysin were also tested against E. coli clinical isolates. We tested both proteins against three uropathogenic E. coli (UPEC) laboratory strains and eighteen clinical isolates whose fyuA genotype had been previously determined (25) . Of these, all fyuA + clinical isolates and laboratory strains were susceptible to pesticin and hybrid causing 98% and 90% reduction in bacterial viability, respectively (Fig. S7) . Importantly, the bactericidal effect of pesticin and hybrid lysin was observed against recurrent and asymptomatic E. coli clinical isolates indicating that the origin of the strains does not affect bactericidal activity of these proteins; however, neither pesticin nor hybrid lysin is bactericidal against fyuA -strains indicating that these toxin proteins retain specificity for pathogenic subtypes expressing fyuA.
Investigation of Pesticin and Hybrid Action by Cryo-Electron
Microscopy. Next, we used cryo-electron microscopy to visualize changes in cell morphology upon addition of T4 lysozyme, hybrid lysin, and pesticin proteins. Intact cells are too thick to yield useful information except around their periphery where the trilaminar envelope is clearly visualized. In an untreated E. coli fyuA + control sample, almost all observed cells (∼90%) were intact and had normal envelope morphology; however, a small but significant fraction of cells (∼8%) was visibly perturbed and represent the background level of cell disruption that occurs in an untreated culture (Fig. 3A and Fig. S8A ). Addition of hybrid lysin had a dramatic effect; ∼45% of observed cells exhibited gross disruption characterized by vesiculation of the inner and outer cell membranes and loss of cellular integrity (Fig. 3 B and C and Fig. S8 A and E). This kind of vesiculation was not seen when cells were treated with either T4 lysozyme or pesticin (Fig. S8 A, C,  and D) . In contrast to hybrid lysin treatment, the distribution of cell morphologies observed after T4 lysozyme treatment was not altered to a statistically significant degree though the percentage of disrupted cells (∼16%) was slightly higher than the untreated control. Treatment with pesticin resulted in significant but less dramatic disruption of ∼21% of cells (Fig. S8A) . Pesticin disruption appeared distinct from hybrid protein disruption and is characterized by the appearance of holes in the outer membrane and eventual cell rupture ( Fig. S8 C and D) . The distinct morphological characteristics of cells disrupted by the hybrid lysin vs. pesticin may indicate that the two proteins are bacteriolytic through differing mechanisms of action; but, further experiments are required to confirm this.
Transport Across the Outer Membrane. Our bactericidal experiments establish that pesticin and the hybrid lysin require FyuA for transport across the outer membrane, and the electron microscopy images allow visualization of cell destruction once the toxin has entered the periplasm; however, the import pathway remains unclear. If pesticin and the hybrid lysin were transported through the FyuA β-barrel, then unfolding of the bacteriocin would likely be required because the dimensions of the pore do not appear to accommodate fully folded pesticin or hybrid (Fig. 4) . To probe the import pathway further, we created a thermostable hybrid lysin by fusing a fully active T4 lysozyme mutant containing two disulfide bonds (26) to the FyuA-binding domain of pesticin. The disulfide bonds would presumably prevent unfolding of the T4L domain under conditions of the bactericidal assay. To confirm proper fold and disulfide bond formation, the thermostable bacteriocin was crystallized and the structure solved by molecular replacement to 1.8 Å resolution (Table S1 and Fig. S4 B and C) . Although the killing domain of this protein is unlikely to unfold, the thermostable hybrid killed fyuA + E. coli almost as effectively as the "wild type" hybrid with 0.8% survival for the hybrid lysin compared to 10% survival for the thermostable hybrid lysin. This result suggests that the import pathway does not require complete unfolding of the bacteriocin. Discussion T4 lysozyme has long been known to lyse bacteria by disrupting the peptidoglycan layer found between the outer and inner membranes of E. coli; however, this process works from "inside-out" because T4 lysozyme is normally generated within the cytoplasm of a phage-infected E. coli cell where it subsequently facilitates cell lysis and the release of assembled phages. By attaching an FyuA "targeting" domain to the N-terminus of T4 lysozyme, we have been able to make the process work in the opposite direction. This engineered version of T4 lysozyme can be simply added to the external medium and will kill Gram-negative bacteria expressing FyuA without the need for added accessory proteins. Our data show that the engineered viral lysin can traverse the outer membrane in order to reach the peptidoglycan layer. This approach overcomes one of the major limitations to the general use of purified lysins in therapy, i.e., their ability to lyse only Gram-positive bacteria where the peptidoglycan is exposed to the exterior and their lack of effect on Gram-negative bacteria (27) .
By evading the pesticin immunity protein, our hybrid toxin can kill a broader range of pathogenic bacteria giving it a distinct advantage compared to wild type pesticin. Furthermore, Y. pestis Fig. 3 . Cryo-EM of fyuA + E. coli cells treated with the hybrid lysin. Electron micrographs of fyuA + E. coli cells plunge-frozen on holey-carbon mesh coated sample grids. Cells were incubated with (A) no treatment (control) or (B and C) 100 μg∕mL hybrid lysin for 10 min before being plunge-frozen. Extensive membrane breakdown of the treated cell in (B) is apparent. As a result, the cell is weakened and, consequently, spreads and flattens in the thin film of buffer while largely preserving its 3D surface area. As a result, it projects a larger 2D area in the micrograph. Also, as it is so much thinner, the membrane vesiculation is evident all over the cell, not just around the edges. The insets show typical regions of the corresponding cell envelopes at higher magnification. The intact inner membrane (IM), peptidoglycan layer (PG), and outer membrane (OM) are indicated and labeled in (A). Characteristic vesiculation of inner and outer cell membranes is shown in (B) and (C).
uses pesticin to maintain maximal virulence by producing pesticin, Pim, and Pla from the same plasmid (pPCP1). Isolates of Yersinia pestis that do not express Pla due to loss of this plasmid become much less virulent (28, 29) and, because they no longer produce Pim, can be eliminated by pesticin-producing virulent strains. Thus, by creating the hybrid lysin, we have effectively subverted a weapon that Y. pestis uses to maintain maximal virulence and turned it, at least in principle, on itself. In addition, Pim is a periplasmic protein suggesting that pesticin first crosses the outer membrane and is then inactivated by Pim in the periplasm (10) . Because replacing the C-terminal domain of pesticin with T4 lysozyme restores killing of E. coli that express pim, inactivation likely involves an interaction between Pim and the C-terminal domain of pesticin.
This engineered lysin is specifically targeted to the TonB dependent transporter FyuA that is a major virulence factor of several pathogenic bacterial species. Importantly, FyuA is also primarily associated with pathogenic bacteria, and not normal gut flora, allowing our hybrid lysin to target disease-causing bacteria specifically. The physiological role of FyuA is to transport chelated iron against a concentration gradient into the bacterial cell. Iron uptake by this route is, in some cases, essential. FyuA was shown to be required for virulence in a mouse model of plague infection (12, 13) . Together with other genes that make up a genetic feature known as the "Yersinia high pathogenicity island", fyuA is also prevalent in E. coli that are pathogenic to humans including the E. coli strain O104:H4 that caused a recent outbreak of hemolytic uremic syndrome in Germany (14, 15) . High frequencies of fyuA have been demonstrated in genomes of E. coli isolated from blood or urine in disease states like sepsis (30) , urosepsis (31), urinary tract infections e.g., pyelonephritis (32) , and diarrhea (15) . In another study, the presence of the fyuA trait was most closely associated with the ability of E. coli isolates to kill mice in a lethality assay (33) . Additionally, FyuA appears to be critical for efficient biofilm formation by urinary tract infectious E. coli in human urine (34) . Given its clear clinical relevance, FyuA has been proposed as a particularly useful target for therapeutic intervention (35) , and our hybrid lysin thus provides an FyuA-specific tool to potentially combat bubonic and pneumonic plague as well as various E. coli infections. It should be noted that the bactericidal activity of the hybrid toxin will likely need to be improved for it to be medically relevant. Future studies could focus on increasing the efficacy of our hybrid lysin against pathogenic bacteria that carry the fyuA gene perhaps through subtle modifications of the existing construct or by substituting alternate killing domains. From a more general medical perspective, the hybrid lysin approach offers a possibility to target pathogenic Gram-negative bacteria that express specific TonB dependent transporters and to avoid selective pressure on native bacterial flora. Indiscriminate killing of the entire bacterial flora-pathogenic or not-by wide spectrum antibiotics may be contributing to the continuing rise of antibiotic resistance.
Materials and Methods
The complete methods are presented in the SI Material and Methods. The pesticin, pim, and fyuA genes were amplified from Y. pestis (strain 195/P) genomic DNA and cloned into pET vectors (Novagen) for expression. Seleno-methionine derivatized FyuA or pesticin was produced using SelenoMet medium (Molecular Dimensions Limited). FyuA, pesticin, and hybrid lysin were purified using immobilized metal affinity, anion exchange, and size 27 Kbp plasmid (pYptb32953), and a 68 Kbp plasmid (pYV; homologous to pCD1 in Y. pestis). The pYV plasmid is associated with virulence, enabling Ca 2þ dependent growth at 37°C, expression of V and W antigens and expression of certain outer membrane proteins including those involved in type III secretion. All pathogenic species of Yersinia contain the pCD1viru-lence plasmid. Y. pestis also contains two unique plasmids, pPCP1 and pMT1, that encode a variety of virulence determinants. The pPCP1 plasmid encodes the plasminogen activator Pla essential for virulence through the subcutaneous route. Pesticin (pst) and pesticin immunity protein (pim) are also encoded on pPCP1. The pMT1 plasmid encodes murine toxin Ymt and the F1 capsular protein that have been shown to play a role in the transmission of plague. Y. pestis KIM6+ and KIM10+ contain the pathogenicity island on which fyuA is located (thus the + designation); but, they do not contain the 75 kb low calcium response virulence plasmid, pCD1. In addition, KIM10+ has been cured of pPCP1 while KIM6+ has not.
A tandem operon including the open reading frames for pst and pim was amplified from Y. pestis genomic DNA (strain 195/P) by PCR. The amplified product was cloned into a pET16b vector (Novagen) using the XhoI and BamHI restriction sites such that the plasmid contained an N-terminal 7-His tag and Factor Xa protease site followed by the pst gene that was followed by the pim gene. The pim gene has the reverse orientation relative to pst so a putative promoter region upstream of the pim start codon was also included at the 3′ end.
The nucleotides encoding the FyuA TonB type transporter were amplified from Y. pestis (strain 195/P) genomic DNA and cloned into pET20b (Novagen) using the NcoI and HindIII restriction sites such that the expressed protein contained only residues of the mature receptor (23-673) plus two extra N-terminal residues (Met and Gly) as a cloning artifact. The pET20b plasmid contains a PelB signal sequence that allows targeting of FyuA to the E. coli outer membrane. This construct will be referred to subsequently as pET20b-fyuA + . To create pTrc99A-fyuA, a gene coding for the OmpA signal sequence fused to mature wild-type FyuA was synthesized (Biobasic Inc.) and cloned into the NcoI and HindIIl sites of pTrc99A (2) .
All remaining genes used in this study were created by gene synthesis (BioBasic Inc.). Pesticin mutants and the pesticin-T4 lysozyme hybrid were cloned into pET16b. To coexpress FyuA and Pim, a DNA fragment was synthesized that contained the T7 promoter followed by a ribosome binding site and the pim gene. This fragment was cloned into the HindIII and XhoI sites of pET20b-fyuA + in the same direction and downstream of fyuA. To express and purify T4 lysozyme, a gene fragment containing a 10X histidine tag followed by a TEV site and T4 lysozyme was synthesized and cloned into the NcoI and HindIII sites of pBAD/HisA (Invitrogen). The wild type sequence of T4 lysozyme (3) was modified to substitute cysteines at position 54 and 97 with Thr and Ala, respectively (4) in order to prevent possible intermolecular disulfide formation. We also cloned pesticin and the hybrid lysin into pET28a. For these constructs a 10-His tag followed by a TEV protease site is directly upstream of the pesticin or the hybrid gene. These constructs were used to express and purify pesticin and hybrid for the bactericidal assays in Fig. 2 A-C. For all other experiments, pesticin, the pesticin mutants, and the hybrid lysin were expressed and purified using the pET16b constructs.
Purification of pesticin and FyuA for X-ray crystallography. Cells were grown in SelenoMet Medium (Molecular Dimensions Limited) supplemented with 100 μg∕mL carbenicillin and 40 μg∕mL L-selenomethionine to an OD 600 ¼ 0.6 at 37°C with a subsequent induction using 1 mM IPTG and continued growth at 25°C for 12 h for pesticin. Growth for FyuA was the same except that no IPTG was added and the cells were grown at 37°C for approximately 60 h to an OD 600 of about 2.
For pesticin purification, 20 g of cells were resuspended in 100 mL of 50 mM K 2 HPO 4 at pH 7.5, 200 mM NaCl, 10 mM MgCl 2 , 10 μg∕mL DNase I, and 100 μM AEBSF. The cells were then disrupted in an Emulsiflex-C5 (Avestin) homogenizer (four passes, 18,000 psi, 4°C). Following centrifugation (160;000 × g, 1 hour, 4°C) the clarified supernatant was applied to a 15 ml Ni-NTA column (Qiagen) equilibrated with 50 mM K 2 HPO 4 at pH 7.5, 200 mM NaCl and 10% glycerol (vol∕vol). Pesticin was eluted using an imidazole step gradient. Protein containing fractions were then pooled and dialyzed at 4°C for 12 hours against 50 mM Tris-HCl at pH 8.0, 100 mM NaCl, 1 mM EDTA. The sample was then filtered using a 0.22 μm filter and further purified by anion exchange using a 10 ml Q-sepharose high performance column (GE Healthcare) equilibrated in 50 mM Tris-HCl at pH 8.0, and 1 mM EDTA. A linear NaCl gradient was used to elute the protein. Peak fractions were pooled and applied to a Sephacryl 300 16/60 column (GE Healthcare) equilibrated with 20 mM Tris HCl at pH 8.0, 200 mM NaCl, 1 mM EDTA, and 0.02 % NaN 3 (wt∕vol). The essentially pure pesticin peak was concentrated (Centriprep YM-10) to a final concentration of 12 mg∕mL for use in crystallization.
The FyuA protein was detergent solubilized and purified by three chromatography steps (5) . In brief, FyuA was extracted from the cell membrane with the use of 5% vol∕vol ELUGENT (Calbiochem). Then, the protein was applied to a nickel column in the presence of 0.01% dodecyl maltoside (DDM), the His 10 -tag was cleaved with TEV protease , and the cleavage step was followed by ion exchange in the presence of 0.01% DDM. The final gel filtration step was carried out on a column equilibrated with 20 mM Tris·HCl at pH 7.5, 200 mM NaCl, 0.02% NaN3, and 0.05% dodecyl dimethylamine oxide. 0.45% wt∕vol octyl tetraethylene glycol monoether was added to the purified peak fraction, and the protein was concentrated to 12 mg∕mL. Final protein yields ranged from 5 to 10 mg of purified FyuA per 30 g of frozen cells.
Purification of pesticin, pesticin point mutants, and the hybrid protein for bactericidal assays. The above protocol was slightly modified to prepare pesticin and its point mutants for in vivo bacteriocidal assays. Cells were grown in Novagen Overnight Express TB Autoinduction Media at 37°C to stationary phase densities. After Ni-NTA purification, the N-terminal His tag was cleaved to avoid the possibility that the tag would interfere with the function of the TonB box that is found close to the N-terminus. To cleave the tag, 5 mM CaCl 2 and Factor Xa protease (10 U per 1 mg of pesticin) were added to the dialyzed protein and incubated at room temperature for 12 h. The anion exchange step was omitted in the purification protocol, and the cleaved protein was applied directly to a Sephacryl 300 16/60 column equilibrated with 20 mM Tris HCl at pH 8.0, 200 mM NaCl. The protein peak was concentrated to between 2-10 mg∕mL.
Further alterations to the protocol were made to reduce precipitation of the hybrid protein to negligible amounts: Cells were grown to stationary phase densities at 20°C instead of 37°C. All purification steps were performed strictly at 4°C including the Factor Xa cleavage step. Consequently, the incubation period where the hybrid protein was incubated with Factor Xa was extended to 48 h. The salt content of all buffers was raised to 500 mM NaCl, and the pH of all buffers was maintained at pH 7.5. The dialysis buffer also contained 10% glycerol (vol∕vol). The final hybrid protein peak was concentrated to 2 mg∕mL. Pesticin and the hybrid lysin were expressed and purified using the pET28a constructs as described above except that TEV protease was used to cleave off the N-terminal tag instead of factor Xa.
Purification of T4 lysozyme for bactericidal assays. Cells were grown in 1 liter of 2x YT broth (MP Biomedicals) supplemented with 100 μg∕mL carbenicillin to OD 600 of 2.0 at 37°C. Protein expression was induced by the addition of 0.04% arabinose (wt∕vol), and the cells were cultured for a further 2 h at 37°C. The cultures were then centrifuged at 4,800 rpm for 20 min at 4°C. During centrifugation, the cells underwent a partial autolysis. Two micrograms per milliliter of DNAse I was then added to the centrifugation supernatant, and the supernatant was filtered through a 0.2 μm filter. Fifteen milliliters of Ni-NTA agarose (Qiagen) resin was then added to the supernatant and briefly agitated. The resin was then collected in a column that was subsequently equilibrated with 50 mM K 2 HPO 4 at pH 7.5, 200 mM NaCl and 10% glycerol (vol∕vol). T4 lysozyme was eluted using an imidazole step gradient. The collected peak fractions were then dialyzed against 20 mM Tris HCl at pH 8.0, 200 mM NaCl. Finally, the dialyzed protein was concentrated to 5 mg∕mL.
Crystallization and structure determination. For the pesticin structure, crystals were grown by the hanging drop vapor diffusion method in 24-well Linbro Plates (Hampton Research) at 21°C. The concentrated pesticin protein (1 μL) was mixed with 1 μL of 20% wt∕vol PEG3350 and 0.25 M CaCl 2 . Prior to freezing, the crystals were cryoprotected by the addition of 20% glycerol (vol∕vol) to the mother liquor. The crystals were flash frozen in liquid propane, and X-ray diffraction data were collected at 100 K, at beamline SER-CAT 22-ID, Advanced Photon Source (Argonne, IL). A MAD data set was collected at the peak, edge, and remote wavelengths of 0.97925, 0.97939, and 0.97172 Å, respectively. Data were integrated and scaled with HKL2000 (6). Programs implemented by PHENIX (7) were used to locate the selenium sites for density modification and initial autobuilding. The initial model was improved by iterative cycles of manual rebuilding in Coot (8) and refinement in Refmac (9) . Six hundred and forty eight residues in the asymmetric unit were evaluated in total by Molprobity Ramachandran analysis (10); 97.8% of all residues were in favored regions. One hundred percent of all residues were in allowed regions. There were no Ramachandran outliers.
Crystals for the hybrid lysin and thermostable (TS) hybrid lysin were grown using conditions established for pesticin and diffracted to 2.6 Å and 1.8 Å resolution, respectively. We collected diffraction data at SER-CAT and GM/CA-CAT beamlines and solved both structures by molecular replacement using the pesticin and T4 lysozyme coordinates (PDB code 2LYZ).
FyuA was crystallized by mixing 0.5 μL protein with 0.5 μL of well solution containing 2.4 M Ammonium Formate and 0.1 M Hepes at pH 6.8. Diffraction data were collected at the SER-CAT 22-ID beamline at the Advanced Photon Source (Argonne, IL). We solved the structure of FyuA in its unliganded form by the SAD method to a resolution of 3.2 Å.
Bactericidal and growth inhibition assays. T7 express cells containing empty pET20b, pET20b-fyuA + , or pET20b-fyuA + pim + were grown to an OD600 of ∼0.3 in LB medium supplemented with 100 μg∕mL carbenicillin. The cells were then washed and adjusted to an OD600 of 0.1 with PBS containing 100 μg∕mL carbenicillin. Pesticin or hybrid protein (diluted in PBS) was added to the treated samples to a final concentration of 100 μg∕mL. The cells were then shaken at 37°C. At each time point, the cells were washed, diluted with cold PBS, and then pipetted onto LB plates containing 100 μg∕mL carbenicillin. After overnight incubation at 37°C, colonies were counted to determine cell survival. To test the relative bactericidal activities the pesticin active site mutants and T4 lysozyme, pET20b-fyuA + cells were cultured to an OD 600 of 0.3 in LB medium supplemented with 100 μg∕mL carbenicillin. Pesticin, hybrid, and pesticin mutants E178A, E178A þ T201A, T201A, P178D were added to individual culture tubes to a concentration of 100 μg∕mL and T4 lysozyme to a final concentration of 53 μg∕mL. As a positive control, 53 μg∕mL of T4 lysozyme and 800 μg∕mL EDTA were added to the same culture tube (Fig. S3) . All tubes were incubated for 20 min before dilution and plating.
Bactericidal activity of pesticin and hybrid lysin was also tested against E. coli clinical isolates. We examined whether the bactericidal activity of pesticin and hybrid lysin is species specific or whether their bactericidal functions are fyuA specific and, therefore, generalizable to other fyuA + strains. We tested the bactericidal effects of both proteins against three uropathogenic E. coli (UPEC) laboratory strains and 18 clinical isolates whose fyuA genetype has been previously determined (11) . For these assays, the clinical isolates were first grown in LB medium and then subcultured into M63 minimal medium containing 0.2% glycerol. The cells were then shaken O \ N at 37°C and adjusted to an OD 600 of 0.1 with fresh M63 minimal medium. Pesticin or the hybrid lysin was added to a final concentration of 100 μg∕mL, and the cells were incubated at 37°C with shaking for 100 min. The cells were then diluted in PBS, dispensed onto Luria broth (LB) agar plates, and the surviving colonies counted the next day.
For the pesticin growth inhibition assay, MG1655 (F-lambdailvG-rfb-50 rph-1) cells harboring pTrc99A-fyuA were grown in LB medium containing 100 μg∕mL carbenicillin at 37°C with shaking. When the culture reached an OD 600 of approximately 0.1, it was split into 2 mL aliquots, and purified pesticin was added to varying concentrations. The OD 600 of the cultures was measured approximately every 20 min to monitor cell growth.
Top agar plate assays. LB top agar was prepared (12) . The following strains were tested: E. coli BL21(DE3) transformed with pET20b-fyuA + or pET20b only. The cells were grown in LB media supplemented with 100 μg∕mL carbenicillin. Molten LB top agar (3 mL) was added to 8·10 8 cells and poured onto LB agar plates supplemented with 100 μg∕mL carbenicillin. Serial dilutions of pesticin or the hybrid protein were applied to the plates and the plates were incubated at 37°C for 16 h. Appearance of clear zones was taken as evidence of pesticin or hybrid sensitivity.
In the case of Yersinae-Y. pestis KIM6+, Y. pestis KIM10+, and Y. pseudotuberculosis-the cells were grown in iron-deficient (ID) media prepared as described by Perry and Brubaker (13) with the exception that the final iron extraction was carried out with Chelex-100 (Sigma) instead of 8-hydroxyquinoline. Forty grams of Chelex-100 was washed with 1.5 L of water and then added to 0.5 L of ID media. The mixture was then stirred for 1.5 h, and the Chelex-100 was removed by filtration. The pH was adjusted to 7.5 with NaOH. To prepare ID plates, the media was solidified by the addition of 1.5% agar (wt∕vol) for the bottom layer and 0.7% for the top agar layer (wt∕vol).
Cultures of Yersiniae were grown 24 h in LB media and subcultured into ID media. After 24 h growth in ID media, the cells were subcultured into fresh ID media, grown for 24 h and used in top agar plate assays. Molten ID top agar (3 mL) was added to 8·10 8 cells and poured over ID agar plates. Dilutions of pesticin or the hybrid protein were spotted onto the top agar and the plates were incubated for 16 h at 37°C Using the plate assay described above, we also tested three Gram-positive strains provided by D. Nelson (U. Maryland Biotechnology Institute) for sensitivity to pesticin and hybrid. These were Streptococcus pyogenes, strain D471 (group A Streptococcus), Staphylococcus aureus, strain RN4220, and Enterococcus faecalis, strain EF24. Strains were grown in brain-heart infusion broth. None of the strains exhibited sensitivity to either toxin perhaps because pesticin and the hybrid lack the carbohydrate binding domains found in lysins that target Gram-positive organisms and/or because peptidoglycans differ chemically (S. aureus contains 6-O-acetylated peptidoglycans that are not cleaved by T4-type lysins).
Electron microscopy. E. coli T7 express cells transformed with pET20b-fyuA + were cultured at 37°C, 220 rpm to an OD 600 of 0.6. The hybrid, T4 lysozyme, or pesticin protein was added to the cells to a final concentration of 100 μg∕mL (hybrid, pesticin) or 53 μg∕mL (T4 lysozyme) and the cells were incubated at 37°C for 10 min. Control cells were incubated in media at 37°C for ten minutes without protein treatment. Solutions of E. coli samples were applied to Quantifoil holey carbon grids (Quantifoil Micro Tools GmbH, Germany), blotted and plunge-frozen in liquid ethane with a Vitrobot (FEI, Hillsboro, OR, USA). Grids were imaged using a Technai T12 (FEI, Hillsboro, OR) electron microscope operating at 120 kV equipped with an energy filter operated in zero-loss mode. Images were captured on a 2kx2k CCD camera (Gatan, Pleasanton, CA) at magnifications ranging from 21,000× to 38,500× (14.3-7.8-Å pixel size). Electron dose per image ranged from 5-10 e − ∕Å 2 and images were recorded at −4 to −6 μm defocus. Fig. S1 . The C-terminal domain of pesticin resembles T4 lysozyme structurally. Pesticin does not share sequence homology with any other bacterial colicin (except for the TonB box motif) or any other protein currently in the Protein Databank (PDB). Therefore, the pesticin fold was analyzed using the DALI server in order to identify structurally similar proteins. For the N-terminal domain, DALI analysis did not yield an unambiguous structural alignment. Only 62 residues out of the 164 residues of the N-terminal domain could be structurally aligned with a significant Z score of 3.1 to the C2 binding domain of the intracellular CD2 binding protein CD2BP2 (1) . A much more definitive alignment was obtained for the C-terminal domain of pesticin. Here, a high Z score match of 8.9 was obtained to the lysozyme domain of the gp5 component of the cell-puncturing device of bacteriophage T4 (2) . Therefore, despite not sharing any sequence similarity to T4 or other phage lysozymes, based on its structure the C-terminal domain of pesticin can be assigned to the phage lysozyme family (within the lysozyme-like superfamily) according to SCOP classification (3).
DaliLite structure-based sequence alignment of the pesticin C-domain with T4 lysozyme (PDB ¼ 2LZM). The alignment identified 23 identical residues that are shared between T4 lysozyme and the C-terminal pesticin domain comprising 14% of the residues in T4 lysozyme. Active site residues are highlighted in red, and the residues mutated in this study are indicated with an asterisk. A comparison of the secondary structure elements between the two structures is also shown. α-helices are represented in pink and β-strands in light green. For completeness, the N-terminal domain of pesticin is also shown. Residues in boxes represent parts of the structure having poor electron density (i.e., not aligned in Dalilite). . Bactericidal assays for pesticin active site mutants. Pesticin, mutant pesticin, hybrid lysin, or T4 lysozyme was added to E. coli transformed with pET20b-fyuA + . Samples were taken after a 20 min incubation, plated, and surviving bacterial colonies were counted. Mutating pesticin residues E178 or T201 to Ala completely abolishes activity; whereas, mutating P187 to Ala results in partial inactivation. Mutating P178 to Asp (mimicking T4 lysozyme) was expected to increase pesticin's activity but also results in inactivation. These experiments suggest that E178 and T201 are of primary importance in the reaction with P187 having a secondary role. To demonstrate that T4 lysozyme does not kill cells unless it gains access to the periplasm, cells were treated with 53 μg/mL T4 lysozyme or 53 μg∕mL T4 lysozyme plus 800 μg∕mL EDTA. EDTA permeabilizes the outer membrane allowing T4 lysozyme to degrade the peptidoglycan layer. This results in cell death. Compared to other bacteriocins, relatively high levels of pesticin and the hybrid were required to kill the E. coli in this assay; however, concentrations used here are similar to HEWL lysozyme concentrations routinely used to lyse Gram-negative cells in combination with EDTA (1). Fig. S3 . Sequence details of the proteins purified in this study. His tag and cloning artifacts for the pET16b constructs are highlighted in cyan, the TonB box motif in magenta, and active site residues in orange. The residues mutated in this study are marked with an asterisk. The position of the Factor Xa cleavage site is indicated with a triangle symbol. For the hybrid protein, the portion derived from pesticin is shown in lowercase and the portion derived from T4 lysozyme in uppercase. For the pET28a constructs expressing pesticin or the hybrid lysin, the sequence highlighted in cyan was replaced with a 10-His tag followed by a TEV protease cleavage site (mhhhhhhhhhhenlyfqs). In contrast, a final concentration of 0.15 μg∕mL of colicin Ia completely inhibited cell growth; whereas, a higher final concentration (15 μg∕mL) allowed cell growth that was similar to the untreated control (1). In the same study, Jakes et al. showed that each molecule of colicin Ia requires two Cir receptors: one for binding and one for cell entry and subsequent killing. Thus, at high concentrations, colicin Ia inhibits itself by binding to all of the available Cir receptors leaving none for outer membrane translocation. Because pesticin inhibits growth equally at high and low concentrations, our data suggest that pesticin does not require two copies of its receptor (FyuA) for cell binding and entry. . Bactericidal culture assays for uropathogenic E. coli (UPEC) strains. To provide additional direct evidence that the FyuA receptor is essential for killing, we assessed three fully sequenced E. coli strains (MG1655, UTI189, and CFT073) and eighteen previously characterized UPEC strains (clinical isolates) (11) for susceptibility to pesticin and hybrid. The chart demonstrates that sensitivity to pesticin and hybrid correlates with expression of fyuA. Fig. S8 . Morphological effects of protein treatment observed by electron microscopy. T7 Express cells expressing FyuA were treated with protein and observed by cryo-EM as described. (A) Individual cell morphology was classified as "normal" or "disrupted" based on overall cell condition. Untreated control cells were >90% "normal" (n ¼ 106). A significant percentage of hybrid and pesticin treated cells were classified as "disrupted" (45%, n ¼ 98; 21%, n ¼ 76, respectively). Over 80% of T4 lysozyme treated cells appeared to be normal, a difference that was not significant from control cells (n ¼ 55). (B). Individual morphological defects were also tracked; several were found to correlate with protein treatment. Treatment with pesticin caused a significant rise in the appearance of holes in the outer membrane and ruptured cells. 
